Key highlights of 2024
Portfolio
Successful acquisition of the global rights to Enjaymo from Sanofi. On November 29th, the Group announced the closing of the acquisition for the global rights to Enjaymo from Sanofi. Integration is proceeding on track, with sales of €10.9 million in December 2024.
Enjaymo® is a biologic that is the only approved targeted product for the treatment of cold agglutin disease (CAD), a rare B-cell lumphoproliferative disorder. The acquisition of Enjaymo® reinforces our commitment to addressing the needs of patients with limited treatment options and is an excellent fit with our existing business.
Sustainability
People
In 2024, a Diversity & Inclusion network including around 60 champions across the world was set up to nurture this important culture pillar, with a first ambitious target to sign Diversity & Inclusion charters in all European countries where we operate.
Product Pipeline & Future Developments
We are expanding our commitment to researching and developing treatments for rare diseases and have a number of projects in the pipeline in various development phases.
Patient Care
Our approach towards patients is evident in the projects we initiated during 2024: the Patient Ambassador Group and the development of the Patient Community Charter together with our patient community.
Full Report